FDAsafety guidance66% confidence
FDA TA — BINIMETINIB (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Alembic Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA217678. Sponsor: ALEMBIC PHARMS LTD. Submission status: TA. Submission type: ORIG. Review priority: STANDARD. Active ingredients: BINIMETINIB.
Supporting Context
- Therapeutic area
- Oncology · MEK Inhibitor
- Sub-indication
- General
Related signal: FDA Acceptance of Binimetinib Application by Alembic Pharmaceuticals